Albireo to Present at the William Blair Biotech Focus Conference 2020
Albireo Pharma (Nasdaq: ALBO), a clinical-stage biopharmaceutical company, announced that CEO Ron Cooper will participate in a fireside chat at the William Blair Biotech Focus Conference 2020 on August 6 at 2 p.m. EDT. The presentation will be available live via webcast on Albireo’s Media & Investors page, with a recommendation to register 15 minutes before the event. An archived version will be accessible for two weeks post-event. Albireo focuses on innovative bile acid modulators for treating orphan pediatric liver diseases, with its lead candidate, odevixibat, advancing in Phase 3 development.
- None.
- None.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT.
The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.
Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568
Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com
FAQ
When is Albireo Pharma's CEO presentation at the William Blair Biotech Focus Conference?
How can I watch Albireo Pharma's presentation at the August conference?
What is the primary focus of Albireo Pharma's development?
What is the status of Albireo's lead product candidate, odevixibat?
Where is Albireo Pharma located?
